Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Taking Ownership Over Cholesterol Management: Multidisciplinary Expert Perspectives

Program Information

Program Information

ReachMD Healthcare Image

How can cardiologists and PCPs coordinate post-MI care, and what treatment options can help VHR patients meet LDL-C guidelines?

  • Overview

    In VHR patients who have suffered a recent myocardial infarction (MI), even high intensity statins may not be able to lower LDL-C levels to reach the recommended guideline thresholds to help prevent a future MI, stroke, or coronary vascularization. In fact, about 1 in 5 patients who’ve had an MI will have another CV event (composite of ischemic stroke, recurrent MI, or all-cause death) within one year. That’s why preventive and invasive cardiologist Dr. Janki B. Shah and family practice physician Dr. J. Kyle Turnbo join Dr. Charles Turck to share multidisciplinary collaborations in cholesterol management and the role of Repatha® (evolocumab) in treating high-risk patients with cardiovascular disease.

  • Important Safety Information

    Repatha® is indicated:

    • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
    • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol
      (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

    Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

    Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

    Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

    From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash, eczema, erythema, and urticaria.

    Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus, nasopharyngitis, and upper respiratory tract infection.

    Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

    Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

    Please see link to full Prescribing Information

Schedule27 Jun 2022
Webpack App